351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (1900)
- Addiction (16)
- Allergy, Asthma, & Immunology (12)
- All of Us Research Program - NIH (1)
- (-) Autoimmune Disorders (28)
- Blood Disorders (38)
- Bone & Muscle (10)
- Cancer
(726)
- Bladder Cancer (14)
- Brain Cancer (25)
- Breast Cancer (70)
- Gastrointestinal (16)
- Gynecologic Cancer (28)
- Head and Neck Cancer (4)
- Kidney Cancer (8)
- Leukemia (75)
- Liver Cancer (10)
- Lung Cancer (62)
- Lymphoma (45)
- (-) Multiple Myeloma (30)
- Pancreatic Cancer (22)
- Prostate Cancer (36)
- Sarcoma (25)
- Skin Cancer (30)
- Solid Tumors (42)
- Thyroid Cancer (1)
- Uveal Melanoma (7)
- Child Development (4)
- COVID-19 (Coronavirus) (37)
- Critical Illness (1)
- Dental (2)
- Developmental Disorders (2)
- Diabetes (22)
- Ear, Nose and Throat (11)
- Endocrine & Metabolic Disease (13)
- Eye (8)
- Gastrointestinal and Digestive Diseases (22)
- Hair and Skin Disorders (2)
- Headaches (5)
- Healthy Volunteers (175)
- Heart Disease (128)
- Infectious Disease (48)
- Insomnia (2)
- Kidney Disease (12)
- Liver Disease (48)
- Lung Disease (32)
- Meniere's Disease (1)
- Neurological Disorders (174)
- Nutrition (4)
- Obesity (9)
- Obstetrics & Gynecology (51)
- Pain Management (1)
- Pediatrics (104)
- Psychiatric Disorders (65)
- Rehabilitation (8)
- Stroke (7)
- Surgery (7)
- Transplant (51)
- Urology (4)
- Vascular Conditions (9)
Displaying 1 - 70 of 70
Study of Daratumumab in Addition to Chemotherapy for Patients with Smoldering Multiple Myeloma (SMM)
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see if Isatuximab can alter the immune system favorably in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. This study will have two arms. On one arm (control arm), Participants will receive standard transplant procedures and on the other arm (experimental arm),…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is looking at people who have recently been newly diagnosed with a type of cancer called multiple myeloma (NDMM). The purpose of this study is to learn about the safety, tolerability (how your body reacts to the study drug), and effectiveness (tumor shrinkage) of linvoseltamab (called study drug) in participants with NDMM as a first step in…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to test whether BMS-986393 in combination with other anti-cancer drugs is safe and effective at treating people with multiple myeloma (MM) that has come back after previous treatment (relapsed) or is not responding to current treatment (refractory). The researchers think that the combinations of alnuctamab, mezigdomide, or…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
This study is the first time REGN5458 will be combined with other cancer therapies. The main goal is to understand if REGN5458 can be given safely with other cancer study treatments, and if so, what dose of REGN5458 should be used for each combination. The investigational drug, REGN5458, is not approved by the Food and Drug Administration (FDA).
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Currently Recruiting
The purpose of this study is to see how teclistamab by itself compares to study treatment combinations that are commonly used to treat multiple myeloma. These study treatment combinations are either pomalidomide, bortezomib and dexamethasone (called PVd) or carfilzomib and dexamethasone (called Kd). The patients will be randomly assigned to on of the study…
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Currently Recruiting
The purpose of this study is assess the safety, safest dose, and effectiveness of venetoclax in combination with dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) light chain amyloidosis. Furthermore, the purpose of phase 2 part of this study is to compare the effectiveness of venetoclax and…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Currently Recruiting
The purpose of this study is to develop a cohort of patients with early scleroderma and to collect data on clinical outcomes, radiological tests, laboratory tests, and to obtain biological specimens for testing.
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Currently Recruiting
This research is being done to determine how variations in genes may explain the different risks to develop scleroderma (or CREST) seen in African American patients compared to other populations. People who are African American with scleroderma (or CREST) may join. This research involves a blood draw and physical exams.
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to determine if the investigational therapy called bb2121 is effective in treating multiple myeloma. bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T-cell therapy. T cells are a kind of white blood cell which form part of your body's immune system. Your T cells will be separated from the rest of the…
Condition: Autoimmune Disorders
Investigator: Olatundun Williams, MD
Status: Closed
The purpose of this study is to understand the life course of PIRD patients and their family members that have the same gene change but do not have the same symptoms. PIRD is mostly due to inherited changes in the genes that normally have immune cells fight infections and regulate the immune system. There are many types of problems that patients with PIRD…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to see if Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by cilta-cel is safe and useful for treating patients with newly diagnosed Multiple Myeloma, as compared with the use of VRd followed by Lenalidomide and Dexamethasone (Rd) therapy. Cilta-cel is a CAR-T cell therapy. In this type of treatment, your white blood…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
This study will look at the safety of a drug (REGN5458) in patients with multiple myeloma. It will also try to find out what the best dose of REGN5458 is and look for any signs that REGN5458 can help treat your cancer. REGN5458 is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) for any condition.
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Jon Giles, MD
Status: Closed
We are inviting patients with active Rheumatoid Arthritis (RA) to help us better understand how treatment options affect inflammation in soft tissues. With a combination of blood work, a full-body FDG PET-CT scan, questionnaires, and a soft tissue biopsy (from an area around the belly button), we hope to see how RA interacts with these multiple areas of…
Condition: Autoimmune Disorders
Investigator: Jon Giles, MD
Status: Closed
We are looking for patients who have been diagnosed with Psoriatic Arthritis (PsA) to help us better understand the involvement of inflammation on the body. With a combination of bloodwork, a bone density scan, questionnaires, and a one-time soft tissue biopsy (from an area around the belly button), we hope to see how PsA interacts with these multiple areas…
Condition: Autoimmune Disorders
Investigator: Brian Henick, MD
Status: Closed
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this study is to determine if the investigational therapy, bb2121, in combination with other treatments, is safe and effective in treating relapsed and/or refractory multiple myeloma.
Condition: Cancer / Multiple Myeloma
Investigator: Rajshekhar Chakraborty, MD
Status: Closed
You are being asked to participate in this study because you have multiple myeloma that has either returned after your most recent treatment regimen or has not responded to your most recent treatment regimen. Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making…
Condition: Autoimmune Disorders
Investigator: Peter Green, MD
Status: Closed
This research study is sponsored by ImmunogenX and The National Institutes of Health (NIH, Bethesda, MD). The objective of this study is to determine if the investigational product (latiglutenase) will help decrease symptoms in subjects with celiac disease while maintaining a gluten-free diet while undergoing periodic gluten exposure. In addition, this…
Condition: Autoimmune Disorders
Investigator: Marcella Walker, MD
Status: Closed
Celiac disease is associated with an increased risk of osteoporosis and fractures. Men with celiac disease were found to be at higher risk for metabolic bone disease compared to women with celiac disease. The mechanisms underlying metabolic bone disease in celiac disease remain incompletely understood. The goal of this study is to assess skeletal…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
You are being asked to take part in this study because you have Multiple Myeloma. This study is being done to learn more about AMG 701 in people with Multiple Myeloma. It will see if AMG 701 is safe and tolerable and whether it causes any side effects. This study will also look at what doses of AMG 701 are safe for people to take and what the effect on…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study. We invite you to participate in this research study because you have been diagnosed with Multiple Myeloma (MM). Your previous treatment(s) has/have not been successful and your cancer is progressing. The purpose of this research study is to see if selinexor (also known as KPT-330) has any effects on your cancer. Selinexor is…
Condition: Cancer / Multiple Myeloma
Investigator: Ran Reshef, MD
Status: Closed
The purpose of this research study is to obtain information on the safety and effectiveness of PBCAR269A to treat certain types of cancers. PBCAR269A is a new investigational treatment for certain types of cancer of the blood, such as multiple myeloma. It is made from a type of blood cells known as T cells. The T cells in PBCAR269A came from people who have…
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Laura Geraldino-Pardilla, MD, MPH
Status: Closed
This study aims to understand how two commonly prescribed drugs impact myocardial inflammation in rheumatoid arthritis.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Nobuko Hijiya, MD
Status: Closed
We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects…
Condition: Autoimmune Disorders
Investigator: Runsheng Wang, MD
Status: Closed
This is a 6-week randomized, double-blind trial of 4 different non-steroidal anti-inflammatory drugs in patients with axial spondyloarthritis to compare the change of pain score from baseline at 4 weeks to the change of pain score from baseline at 6 weeks. Patients with ankylosing spondylitis or axial spondyloarthritis who fulfills the inclusion and…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
If you have active Systemic Lupus Erythematosus, also known as SLE or Lupus, you may be interested to learn about a clinical research study that is being conducted to study the safety and effectiveness of an investigational medication called ustekinumab for active Lupus. Eligible study participants will be provided with study medication and study-related…
Condition: Autoimmune Disorders
Investigator: Anca Askanase, MD, MPH
Status: Closed
In this experimental study, researchers will try to find out if treatment of lupus nephritis with a combination of rituximab and cyclophosphamide (CTX), or a combination of rituximab and CTX followed by treatment with belimumab is safe and if this drug combination can block the immune system attacks.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Julia Glade Bender, MD
Status: Closed
The purpose of this study is to assess the safety and effectiveness of a study drug called axitinib on treating tumors that have returned (recurrent) or have not responded to standard therapy (refractory). Children will take axitinib twice a day for 28 days (1 cycle). Children may take study drug for up to 24 cycles (2 years).
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by fibrosis and atrophy, namely of the skin, internal organs, joints, and skeletal muscles. There are numerous manifestations of SSc that affect multiple organ systems. The major pulmonary manifestations of SSc, interstitial lung disease and systemic sclerosis-associated…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this study is to look at what happens (both good and bad) when daratumumab is given with two other drugs called VELCADE and dexamethasone compared to just giving those two drugs, VELCADE and dexamethasone, alone. VELCADE is also known by the name bortezomib. Giving VELCADE and dexamethasone together is standard treatment for advanced multiple…
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Joan Bathon, MD
Status: Closed
The study aims to compare the effect two different RA treatments on cardiovascular health in patients who are considering a treatment change. The study is recruiting patients who are only taking methotrexate and are switching treatment due to a lack of improvement. The trial will randomize participants to take a TNF inhibitor (Enbrel or Humira) in addition…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
The purpose of this study is to determine the effectiveness and safety of a study drug called abituzumab in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The study will also look at the following: How the study drug affects other symptoms of SSc-ILD -How safe the study drug is (i.e. if there are any side effects) -How the…
Condition: Cancer / Multiple Myeloma
Investigator: Siyang Leng, MD
Status: Closed
The purpose of this study is to test the safety, tolerability and anti-tumor activity of the research study drug, pembrolizumab (MK-3475) with or without pomalidomide and low dose dexamethasone in subjects with refractory or relapsed and refractory Multiple Myeloma (rrMM) measured by the rates of response to treatment, disease progression (disease getting…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Stergios Zacharoulis, MD
Status: Closed
The purpose of this study is to find out more about how the study drug called entrectinib will be used in children, adolescents and young adults with treatment-resistant solid tumor in brain or body. This is a phase 1/1b study, divided into a dose escalation portion (different dose will be tested) and a dose expansion portion (one dose will be tested) in…
Condition: Autoimmune Disorders / Lupus
Investigator: Wooin Ahn, MD
Status: Closed
The purpose of this study is to determine if Acthar gel is a safe and effective therapy for patients with membranous (Class V) lupus nephritis. Class V lupus nephritis is associated with the development of chronic kidney disease and end-stage renal (kidney) disease, and there is no clear therapy for treatment. Currently used therapies arent completely…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a study of a study drug, Carfilzomib in combination with bendamustine and dexamethasone for subjects with newly diagnosed multiple myeloma. The purpose of this study is to find the highest tolerable dose of carfilzomib with the combination of bendamustine and dexamethasone. The response rate and the safety of this drug combination will also be…
Condition: Autoimmune Disorders / Rheumatoid Arthritis
Investigator: Joan Bathon, MD
Status: Closed
We are doing a research study to learn more about why people with rheumatoid arthritis (RA) are prone to heart disease. We are recruiting patients diagnosed with Rheumatoid Arthritis without a personal history of heart disease. This study involves one initial full visit as described below, and a brief follow up visit that will take place approximately 2 or…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to compare the effectiveness of venetoclax and dexamethasone versus pomalidomide and dexamethasone in subjects with t(11;14) positive relapsed (comes back) or refractory (did not get better) multiple myeloma.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Stergios Zacharoulis, MD
Status: Closed
The purpose of this study is to find out more about how the study drug called talimogene laherparepvec will be used in children/adolescents/young adults with advanced solid tumors not involving the central nervous system that are available for direct injection. This is a phase 1 study, multicenter, open-label study, that means all subject enrolled in the…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this study is to test the safety and effectiveness of the study drug Obinutuzumab and to find out what effects, good or bad, it may have as an additional therapy in treating your lupus nephritis symptoms.
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
The purpose of this study is to find out whether a drug called iloprost is safe to use in people with systemic sclerosis (SSc) (Raynaud's phenomenon), and whether it may help decrease symptomatic digital ischemic episodes (episodes in the fingers).
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
This is a phase 1/2 multicenter study of AZD1775 (MK-1775) that will be given in combination with irinotecan. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with solid tumors which have come back or have not responded to standard…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
This study is for patients who have been diagnosed with systemic Lupus erythematosus (SLE). SLE is a disease in which the body mistakenly attacks healthy tissue. It can affect the skin, joints, kidneys, brain and other organs. The purpose of this study is to test the effects of an investigational (being tested) study drug, CC 220, in order to find out if CC…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This research study is being done to compare the combination of lenalidomide and dexamethasone followed by autologous peripheral blood stem cell transplant (PBSCT) and lenalidomide and dexamethasone without PBSCT in subjects with untreated multiple myeloma. This comparison will include how many subjects respond to each study treatment combination, how long…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
Belantamab Mafodotin is a new therapy for patients with Multiple Myeloma. The drug works by combining chemotherapy and immunotherapy approach to treat Multiple Myeloma. The drug is a combination of an antibody against a target on plasma cells called BCMA and a chemotherapeutic agent called MMAF. The drug has shown activity in patients with late relapses of…
A study for children with refractory solid tumors, including CNS tumors using study drug ramucirumab
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
The goals of this study are to find the highest safe dose of ramucirumab that can be given without causing severe side effects, to learn what kind of side effects ramucirumab can cause, to learn more about the effects of ramucirumab on cells and proteins in the blood and to determine whether ramucirumab is a beneficial treatment for patients with solid…
Condition: Autoimmune Disorders / Lupus
Investigator: Lisa Imundo, MD
Status: Closed
The purpose of the study is to find out if study drug belimumab is safe and effective in treating children with active lupus who are also taking other lupus medicine. Belimumab (also known as BENLYSTA hasbeen approved in the United States, Canada, and Europe for the treatment of adults with active SLEwho are receiving other lupus medicines but not yet…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to find out how well Daratumumab works when it is given along with two other drugs called Lenalidomide and Dexamethasone compared to the drug combination of Lenalidomide and Dexamethasone to treat multiple myeloma.
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
We are doing this study to learn if the MMprofiler test can help your doctor in making decisions about your treatment. The MMprofiler genomic test will look at a large number of normal genes. The test will predict risk of your multiple myeloma (MM) by assessing whether these genes are turned on or off in your cancer cells. The purpose of this research is to…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
This is a Phase 1 multicenter study of a drug called ABI-009 (nab-Rapamycin) in combination withtemozolomide and irinotecan in children and young adults with solid tumors (including CNS tumors)which have come back or have not responded to standard therapy. The study is considered experimental because ABI-009 (nab-Rapamycin) is not approved by the United…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this study is to evaluate the safety and tolerability of an experimental investigational drug called ixazomib citrate (MLN9708) in patient with Lupus Nephritis. Lupus nephritis is a condition when the kidney is affected in the autoimmune disease known as systemic lupus erythematosus (SLE). SLE is a disease in which the immune system (the body…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is a research study for subjects who have been diagnosed with multiple myeloma, a cancer of plasmacells (a type of immune cell that produce antibodies) in the bone marrow, that has returned (relapsed) or has not responded (refractory) to your most recent treatment regimen.The subject's disease has also progressed after prior treatment with…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Luca Szalontay, MD
Status: Closed
The purpose of this study is to learn what kind of side effects nivolumab as a single agent and nivolumab in combination with ipilimumab can cause and if these treatments are beneficial for solid tumors. Nivolumab (Dose Level 1) will be given as an intravenous infusion every 14 days of a 28 day cycle. If Dose Level 1 is not tolerable, then it will be…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The goal of this study is to test a new lupus drug. This drug interrupts the function of a chemical in the body called IL-6, and IL-6 may be overactive in people with lupus. ALX-0061 is a study drug that will be administered subcutaneously to subjects with moderate to severe active, seropositive Systemic Lupus Erythematosus (SLE) compared to placebo.
Condition: Cancer / Multiple Myeloma
Investigator: Yvonne Saenger, MD
Status: Closed
The purpose of this study is to test two imaging techniques, one called whole body diffusion weighted magnetic resonance imaging (WB-DWI MRI), and another called F-18 3-deoxy-3-fluorothymidine PET (F-18-FLT PET). The goal is to see whether these imaging techniques would allow the study doctors to see changes in the size of a tumor earlier for patients with…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The main goals of this study are to evaluate the safety of the combination of the study drug radium-223 dichloride plus bortezomib and dexamethasone and to determine the optimal dose of radium-223 dichloride to be used in combination with bortezomib and dexamethasone. Radium-223 dichloride has been approved in some countries for treatment of patients with…
Condition: Cancer / Pediatric Solid Tumors
Investigator: Alice Lee, MD
Status: Closed
This study is being carried out by the Childrens Oncology Group (COG) Phase 1 Consortium. COG is an international research group that consists of more than 200 hospitals that treat children with cancer in the United States, Canada, Australia, and Switzerland. The Phase 1 Consortium is the group within COG that consists of 21 hospitals, and participation in…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
The purpose of this study is to determine the efficacy and safety of abituzumab in subjects withsystemic sclerosis-associated interstitial lung disease (SSc-ILD).Abituzumab is an investigational drug that is being evaluated for the treatment of patients withsystemic sclerosis (SSc)-associated interstitial lung disease (SSc-ILD). Systemic sclerosis,…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
This study will look to obtain information on the best dose of the research drug, TAK 079, when administered in combination with other approved multiple myeloma treatments for patients with newly diagnosed multiple myeloma. If you participate you will receive either Arm A (TAK-079 in combination with lenalidomide and dexamethasone) or Arm B (TAK-079 in…
Evaluating the safety and effectiveness of study drug AMG 228 in patients with Advanced Solid Tumors
Condition: Cancer / Pediatric Solid Tumors
Investigator: Yvonne Saenger, MD
Status: Closed
This study is for patients with the following cancers: advanced non-small cell lung cancer, head and neck cancer, melanoma, colon cancer, or bladder cancer. The purpose of this study is to find out more about the effects of AMG 228 in people and on their cancer. AMG 228 is an experimental drug that is being developed to stimulate the bodys immune system to…
Condition: Autoimmune Disorders
Investigator: Thomas Brannagan, MD
Status: Closed
This study is for patients with Lambert-Eaton Myasthenic Syndrome (LEMS). The purpose of this study is to provide doctors and their patients access to amifampridine phosphate therapy for their patients with LEMS, CMS or downbeat nystagmus until the product becomes commercially available. The secondary purpose of the study is to assess the long-term safety…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
This is research study for patients who have been newly diagnosed with Multiple Myeloma (MM). Their previous treatments have not been successful and their cancer is progressing. The purpose of this research study is to see if the study drug selinexor (KPT-330) has any effects against their cancer. This study combines the use of two drugs, selinexor (KPT-…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
We are studying a medication to see if it is effective in reducing the disease activity of systemic lupus erythematosus (SLE), which is the most common form of lupus. You may qualify for the Achtar study if you have persistently active SLE, are 18 years of age or older, and: Have rash and/or arthritis as part of your SLE symptoms Are currently taking…
Condition: Autoimmune Disorders / Lupus
Investigator: Anca Askanase, MD, MPH
Status: Closed
The purpose of this clinical trial is to learn about the ability of an experimental treatment XmAb5871 to maintain lupus disease activity improvement achieved by a brief course of disease-suppressing intramuscular (IM) steroid therapy in lupus patients.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Nobuko Hijiya, MD
Status: Closed
This is a Phase 1 multicenter study of pevonedistat in combination with Temozolomide and Irinotecan in pediatric patients with refractory solid tumors, including CNS tumors and lymphoma. The study treatment is considered experimental because pevonedistat is not approved by the United States (US) Food and Drug Administration (FDA) for treating pediatric…
Condition: Cancer / Multiple Myeloma
Investigator: Divaya Bhutani, MD
Status: Closed
The purpose of this study is to find out whether treatment with daratumumab and lenalidomide will make your Multiple Myeloma better. There are 2 treatment groups in this study. You will either receive lenalidomide alone or both lenalidomide and daratumumab along with medications to take before and after the daratumumab injection.
Condition: Cancer / Pediatric Solid Tumors
Investigator: Julia Glade Bender, MD
Status: Closed
The purpose of this study is to examine the effectiveness and tolerability of a study drug called PF-02341066. Additional goals of this study are to learn how the body handles the study drug as well as determine whether or not PF-02341066 is a beneficial treatment for your tumor This study is for children with a recurrent or progressive tumor or lymphoma…
Condition: Autoimmune Disorders
Investigator: Elana Bernstein, MD
Status: Closed
Systemic sclerosis (SSc) is a systemic connective tissue disease characterized by fibrosis and atrophy, namely of the skin, internal organs, joints, and skeletal muscles. This is a double-blind, placebo-controlled trial to test the efficacy of abatacept (Orencia) on the treatment of diffuse cutaneous systemic sclerosis in patients with a disease duration of…
Condition: Cancer / Multiple Myeloma
Investigator: Suzanne Lentzsch, MD
Status: Closed
The purpose of this research study is to explore the drug combination, lenalidomide, bortezomib, and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects it may have and how well it works for treatment of newly diagnosed multiple myeloma.
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE